Lyell Q4/FY25 net loss $274.4M; Phase 3 PiNACLE-H2H begins; cash $247.2M

Lyell Immunopharma, Inc.

FY25 net loss $274.4M vs $343.0M in FY24; Q4 net loss $140.7M (incl. $66.3M IPR&D for LYL273).
Ronde-cel Phase 3 PiNACLE-H2H (2L LBCL) started dosing; Phase 1/2 PiNACLE 3L+ data shown at ASH 2025.
LYL273 (GCC-targeted CAR-T) Phase 1 dosed 7 more mCRC patients; no DLT; dose escalated to Level 3.
Smital Shah appointed CFO and Business Officer in March 2026; $50M equity tranche closed on milestone.
Cash $247.2M at year-end 2025 (excl. $50M tranche); runway into Q2 2027.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Lyell Immunopharma, Inc. reported financial results for the quarter and full year ended December 31, 2025.

Period: the quarter and full year ended December 31, 2025
Result: reported results

Exact text from the filing

On March 12, 2026, Lyell Immunopharma, Inc. (the “Company”) issued a press release announcing its financial results for the quarter and full year ended December 31, 2025.

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

Lyell Immunopharma, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-26-017244

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.